RAMEZ NASSEF ESKANDER
- Type
- Physician · Allopathic & Osteopathic Physicians / Obstetrics & Gynecology
- Where
- ENCINITAS, CA
- NPI
- 1144486929
- Received
- $706,485 in 526 records, 2019 to 2025
- As principal investigator
- $7,460,305 of research payments to others in 74 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 92 | $169,928 |
| 2024 | General payment | 91 | $111,691 |
| 2023 | General payment | 91 | $115,388 |
| 2022 | General payment | 61 | $78,409 |
| 2021 | General payment | 43 | $63,297 |
| 2020 | General payment | 50 | $65,841 |
| 2019 | General payment | 98 | $101,928 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 161 | $379,756 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 69 | $225,113 |
| Travel and Lodging | 91 | $79,122 |
| Food and Beverage | 195 | $12,945 |
| Honoraria | 6 | $7,325 |
| Education | 4 | $2,221 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Daiichi Sankyo Inc. | $1,453 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | Merck Sharp & Dohme LLC | $2,880 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-02 | BeOne Medicines USA, Inc. | $1,625 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-21 | Gilead Sciences, Inc. | $2,710 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Merck Sharp & Dohme LLC | $7,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | Merck Sharp & Dohme LLC | $123 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-07 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-06 | ABBVIE INC. | $47 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2025 | |
| 2025-11-05 | Corcept Therapeutics | $94 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-04 | Merck Sharp & Dohme LLC | $123 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-31 | AstraZeneca UK Limited | $410 | Consulting Fee | Cash or cash equivalent | ENHERTU Biological, Oncology | 2025 | |
| 2025-10-24 | Genmab U.S., Inc. | $2,000 | Consulting Fee | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-10-17 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-17 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-16 | Genmab U.S., Inc. | $150 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-16 | Genmab U.S., Inc. | $28 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | Merck Sharp & Dohme LLC | $896 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-29 | Merck Sharp & Dohme LLC | $7,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-29 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-09-20 | Merck Sharp & Dohme LLC | $60 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Merck Sharp & Dohme LLC | $161 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-18 | Merck Sharp & Dohme LLC | $9,972 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-18 | Merck Sharp & Dohme LLC | $161 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-18 | Merck Sharp & Dohme LLC | $56 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-18 | Merck Sharp & Dohme LLC | $53 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-17 | Merck Sharp & Dohme LLC | $7,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-12 | BeOne Medicines USA, Inc. | $650 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | Merck Sharp & Dohme LLC | $578 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-11 | Merck Sharp & Dohme LLC | $115 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | Merck Sharp & Dohme LLC | $7,799 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | Genmab U.S., Inc. | $800 | Consulting Fee | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-07-30 | Merck Sharp & Dohme LLC | $10,880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-07-25 | Genmab U.S., Inc. | $3,200 | Consulting Fee | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-07-19 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-18 | Merck Sharp & Dohme LLC | $7,418 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-18 | Merck Sharp & Dohme LLC | $207 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-10 | GlaxoSmithKline, LLC. | $6,400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-09 | BeOne Medicines USA, Inc. | $1,950 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-02 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-01 | Eli Lilly and Company | $2,139 | Education | In-kind items and services | 2025 | ||
| 2025-06-01 | Eli Lilly and Company | $93 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-30 | Corcept Therapeutics | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-30 | Corcept Therapeutics | $132 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-30 | GlaxoSmithKline, LLC. | $95 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-30 | Corcept Therapeutics | $38 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-16 | BeOne Medicines USA, Inc. | $975 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-02 | Regeneron Pharmaceuticals, Inc. | $3,600 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-02 | Regeneron Pharmaceuticals, Inc. | $1,800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-02 | GlaxoSmithKline, LLC. | $1,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-26 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-23 | GlaxoSmithKline, LLC. | $7,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-23 | Eisai Inc. | $2,445 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-07 | Merck Sharp & Dohme LLC | $10,370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-07 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-02 | Eisai Inc. | $3,667 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2025 | |
| 2025-03-31 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-30 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-29 | Merck Sharp & Dohme LLC | $8,870 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-29 | Merck Sharp & Dohme LLC | $635 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-29 | Merck Sharp & Dohme LLC | $158 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-19 | Daiichi Sankyo Inc. | $1,860 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-17 | Regeneron Pharmaceuticals, Inc. | $130 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-17 | Regeneron Pharmaceuticals, Inc. | $37 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-17 | Regeneron Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-14 | Daiichi Sankyo Inc. | $50 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-14 | Daiichi Sankyo Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-12 | Daiichi Sankyo Inc. | $1,860 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-11 | Incyte Corporation | $3,105 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-07 | AstraZeneca UK Limited | $4,100 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-03 | Merck Sharp & Dohme LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-03 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-02-24 | AstraZeneca Pharmaceuticals LP | $685 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-21 | Regeneron Pharmaceuticals, Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-21 | Regeneron Pharmaceuticals, Inc. | $900 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-21 | Karyopharm Therapeutics Inc. | $51 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-02-21 | Merck Sharp & Dohme LLC | $31 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-02-20 | Merck Sharp & Dohme LLC | $43 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-02-19 | ABBVIE INC. | $5,800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-05 | Eisai Inc. | $4,890 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2025 | |
| 2025-02-05 | GlaxoSmithKline, LLC. | $1,809 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $192 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $169 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $62 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $48 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $48 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-05 | GlaxoSmithKline, LLC. | $39 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Eli Lilly and Company | $1,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-16 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-09 | GlaxoSmithKline, LLC. | $1,600 | Consulting Fee | Cash or cash equivalent | JEMPERLI Biological, ONCOLOGY | 2024 | |
| 2024-11-20 | AstraZeneca UK Limited | $4,110 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | GlaxoSmithKline, LLC. | $600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | Merck Sharp & Dohme LLC | $6,710 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | Merck Sharp & Dohme LLC | $5,490 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-11-13 | BeiGene USA, Inc. | $1,950 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-13 | BeiGene USA, Inc. | $1,950 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-12 | GlaxoSmithKline, LLC. | $1,600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-09 | Merck Sharp & Dohme LLC | $55 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-09 | Merck Sharp & Dohme LLC | $48 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-09 | Merck Sharp & Dohme LLC | $45 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $288 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $247 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $208 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $95 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $55 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $48 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-08 | Merck Sharp & Dohme LLC | $45 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Merck Sharp & Dohme LLC | $729 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Merck Sharp & Dohme LLC | $388 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-07 | Merck Sharp & Dohme LLC | $247 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-06 | AstraZeneca UK Limited | $2,460 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-25 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-25 | ABBVIE INC. | $596 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-25 | ABBVIE INC. | $48 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-25 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-25 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-25 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-24 | ABBVIE INC. | $233 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-17 | AstraZeneca UK Limited | $60 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-10-16 | Incyte Corporation | $43 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-10-11 | GlaxoSmithKline, LLC. | $1,600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-07 | Merck Sharp & Dohme LLC | $2,440 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-23 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-09-23 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-09-20 | Regeneron Pharmaceuticals, Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-20 | Regeneron Pharmaceuticals, Inc. | $900 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-16 | Merck Sharp & Dohme LLC | $66 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-16 | GlaxoSmithKline, LLC. | $47 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-16 | GlaxoSmithKline, LLC. | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-15 | Merck Sharp & Dohme LLC | $281 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-15 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-14 | Genmab U.S., Inc. | $131 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2024 | |
| 2024-09-14 | Merck Sharp & Dohme LLC | $40 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-13 | BioNTech SE | $74 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-13 | BioNTech SE | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-12 | Corcept Therapeutics | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2024 | |
| 2024-09-12 | PFIZER INC. | $134 | Food and Beverage | In-kind items and services | TIVDAK Biological, Oncology | 2024 | |
| 2024-09-12 | Corcept Therapeutics | $67 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2024 | |
| 2024-08-28 | Merck Sharp & Dohme LLC | $6,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-20 | Eisai Inc. | $20 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-08-05 | GlaxoSmithKline, LLC. | $2,400 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-19 | ABBVIE INC. | $2,450 | Consulting Fee | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-07-17 | Eisai Inc. | $3,260 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-14 | ABBVIE INC. | $2,800 | Consulting Fee | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-07-14 | ABBVIE INC. | $46 | Travel and Lodging | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-07-08 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-04 | PFIZER INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TIVDAK Biological, Oncology | 2024 | |
| 2024-06-20 | ABBVIE INC. | $86 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-06-20 | GlaxoSmithKline, LLC. | $75 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-18 | ABBVIE INC. | $44 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-06-14 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-02 | Regeneron Pharmaceuticals, Inc. | $99 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-01 | PFIZER INC. | $195 | Food and Beverage | In-kind items and services | TIVDAK Biological, Oncology | 2024 | |
| 2024-05-29 | Eisai Inc. | $3,667 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-05-29 | ABBVIE INC. | $669 | Travel and Lodging | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-05-21 | ABBVIE INC. | $9,495 | Travel and Lodging | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-05-17 | GlaxoSmithKline, LLC. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-24 | Eisai Inc. | $2,445 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-04-03 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-03-21 | Daiichi Sankyo Inc. | $1,240 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-03-18 | Eisai Inc. | $64 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-02-22 | GlaxoSmithKline, LLC. | $2,800 | Consulting Fee | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | 2024 | |
| 2024-02-13 | AstraZeneca Pharmaceuticals LP | $2,740 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-02-10 | AstraZeneca Pharmaceuticals LP | $36 | Food and Beverage (4 payments) | In-kind items and services | 2024 | ||
| 2024-02-01 | F. Hoffmann-La Roche AG | $760 | Consulting Fee | Cash or cash equivalent | Tecentriq Biological, BioOncology | 2024 | |
| 2024-01-29 | Merck Sharp & Dohme LLC | $2,135 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-26 | ImmunoGen, Inc. | $1,400 | Consulting Fee | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-01-26 | ImmunoGen, Inc. | $79 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-01-26 | AstraZeneca Pharmaceuticals LP | $68 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2024 | |
| 2024-01-26 | AstraZeneca Pharmaceuticals LP | $53 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2024 | |
| 2024-01-26 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2024 | |
| 2024-01-24 | Eisai Inc. | $110 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-24 | GlaxoSmithKline, LLC. | $28 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-18 | GlaxoSmithKline, LLC. | $3,600 | Consulting Fee | Cash or cash equivalent | JEMPERLI Biological, ONCOLOGY | 2024 | |
| 2024-01-16 | ImmunoGen, Inc. | $118 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-01-08 | Regeneron Pharmaceuticals, Inc. | $2,641 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-08 | Regeneron Pharmaceuticals, Inc. | $587 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2023-12-22 | AstraZeneca UK Limited | $2,055 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-13 | Eisai Inc. | $2,445 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-08 | BioNTech SE | $2,750 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-08 | GlaxoSmithKline, LLC. | $1,200 | Consulting Fee | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | 2023 | |
| 2023-12-08 | ImmunoGen, Inc. | $80 | Food and Beverage | In-kind items and services | Elahere Biological, Oncology | 2023 | |
| 2023-12-04 | BioNTech SE | $53 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-03 | BioNTech SE | $2,181 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-03 | BioNTech SE | $360 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-30 | SEAGEN INC. | $2,380 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-30 | Daiichi Sankyo Inc. | $1,612 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-22 | Eisai Co., Ltd. | $3,160 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-11-13 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-13 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-11-12 | AstraZeneca Pharmaceuticals LP | $685 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2023 | |
| 2023-11-10 | Regeneron Pharmaceuticals, Inc. | $80 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-10 | Regeneron Pharmaceuticals, Inc. | $67 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-06 | Merck Sharp & Dohme LLC | $6,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 |
The latest 200 records of 526.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | University Of California San Diego Jacobs Medical Center | $840 | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | NRG Oncology | $127,915 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $15,766 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2025 |
| 2025-12-04 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $4,280 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tu | 2025 |
| 2025-11-06 | Genmab U.S., Inc. | Langley Porter Psychiatric Hospital | $17,839 | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i | 2025 |
| 2025-07-17 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $14,797 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tu | 2025 |
| 2025-05-15 | Eli Lilly and Company | REGENTS OF THE UNIVERSITY OF CALIFORNIA | $231,628 | A FIRST IN HUMAN PHASE 1A AND 1B TRIAL TO ASSESS THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF LY4170156 AN ANTIBO | 2025 |
| 2025-04-03 | Genmab U.S., Inc. | UC SAN DIEGO MOORES CANCER CENTER | $35,000 | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i | 2025 |
| 2024-12-31 | Merck Sharp & Dohme LLC | NRG Oncology | $1,047,904 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | NRG Oncology | $1,462,215 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Moores UC San Diego Cancer Ctr | $129,632 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2024 |
| 2024-10-28 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $9,286 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F | 2024 |
| 2024-10-28 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $10,700 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F | 2024 |
| 2024-05-28 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $4,253 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F | 2024 |
| 2024-02-23 | ABBVIE INC. | UC SAN DIEGO MOORES CANCER CENTER | $33,729 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F | 2024 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | UCLA - NEURO ONCOLOGY | $187 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato- | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $28,472 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $18,160 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $1,410 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $20,173 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $3,552 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $13,831 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $9,531 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2023 |
| 2023-10-02 | Novocure Inc. | UC SAN DIEGO MOORES CANCER CENTER | $4,500 | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2023 |
| 2023-07-26 | AstraZeneca Pharmaceuticals LP | UCLA - NEURO ONCOLOGY | $17,290 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato- | 2023 |
| 2023-03-20 | Novocure Inc. | UC SAN DIEGO MOORES CANCER CENTER | $750 | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2023 |
| 2023-03-08 | Epizyme, Inc. | UCSD MOORES CANCER CENTER | $50,000 | A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary | 2023 |
| 2022-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $2,370 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $12,598 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $18,169 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $4,997 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | Moores Cancer Center | $14,156 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | NRG Oncology | $3,159,889 | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC 776864 IN ADDITION TO PACLITAXEL AND CARB | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $26,064 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $2,982 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2022 |
| 2022-10-19 | MACROGENICS, INC. | RAMEZ N ESKANDER MD | $3,000 | 2022 | |
| 2022-10-13 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $6,965 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2022 |
| 2022-09-08 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $16,021 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2022 |
| 2022-08-09 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $3,509 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2022 |
| 2022-07-21 | AstraZeneca UK Limited | UC REGENTS | $66,047 | A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for | 2022 |
| 2022-05-03 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $20,150 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2022 |
| 2022-05-03 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $1,448 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2022 |
| 2022-03-29 | F. Hoffmann-La Roche AG | The Regents of the University of California, San Diego | $3,562 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2022 |
| 2022-02-22 | Novocure Inc. | UC SAN DIEGO MOORES CANCER CENTER | $4,012 | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2022 |
| 2022-02-15 | F. Hoffmann-La Roche AG | The Regents of the University of California, San Diego | $1,251 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2022 |
| 2022-02-01 | F. Hoffmann-La Roche AG | The Regents of the University of California, San Diego | $4,550 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2022 |
| 2022-02-01 | F. Hoffmann-La Roche AG | The Regents of the University of California, San Diego | $4,599 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2022 |
| 2022-01-25 | F. Hoffmann-La Roche AG | The Regents of the University of California, San Diego | $7,067 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2022 |
| 2021-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $26,064 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | UCSD MOORES CANCER CENTER | $20,334 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-30 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $7,218 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-10-14 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $13,299 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-09-29 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $1,462 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-09-28 | Novocure Inc. | UC SAN DIEGO MOORES CANCER CENTER | $32,650 | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 |
| 2021-09-27 | Novocure Inc. | UC SAN DIEGO MOORES CANCER CENTER | $82,650 | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 |
| 2021-09-21 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $46,878 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-08-10 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $20,150 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-08-10 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $22,655 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-08-03 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $26 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-07-27 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $8,284 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-07-07 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $24,999 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-06-24 | AstraZeneca UK Limited | THE REGENTS OF THE UNIVERSITY OF | $56,680 | A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for | 2021 |
| 2021-06-24 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $53,195 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-04-27 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $16,158 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-04-13 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $75,676 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-04-12 | AstraZeneca UK Limited | REGENTS OF THE UNIVERSITY OF CALIFORNIA - UCSF | $69,800 | A Phase 2 Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment | 2021 |
| 2021-03-08 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $3,510 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-02-23 | Clovis Oncology, Inc. | The Regents of the Univ of Californ | $27,780 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2021 |
| 2021-01-25 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $15,307 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2020-12-21 | Clovis Oncology, Inc. | The Regents of The University of California | $57,852 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | 2020 |
| 2020-04-13 | F. Hoffmann-La Roche AG | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $15,671 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2020 |
| 2020-02-12 | PFIZER INC. | The Regents of The University of California | $8,710 | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE | 2020 |
| 2019-07-10 | Genentech, Inc. | REGENTS OF THE UNIVERSITY OF CALIFORNIA TECHNOLOGY TRANSFER OFFICE | $27,820 | BETI SOLID TUMOR PHASE 1B | 2019 |
| 2019-04-29 | Roche Products Limited | UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE | $28,405 | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Encinitas, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) Encinitas, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 61,480 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 62,007 | 3,298,634 | 39,538,223 |
| Median age B01002 | 43.1 | 37.3 | 37.9 |
| Under 18 B01001 | 20.7% | 20.9% | 22.0% |
| 65 and over B01001 | 19.9% | 15.4% | 15.7% |
| Households B11001 | 23,927 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 12.8% | 22.8% | 27.0% |
| Median household income B19013 | $162,229 | $106,268 | $99,122 |
| Median family income B19113 | $184,771 | $122,377 | $113,346 |
| Per capita income B19301 | $84,594 | $51,976 | $49,513 |
| Poverty rate B17001 | 7.4% | 10.3% | 12.0% |
| Unemployment rate B23025 | 4.5% | 6.1% | 6.6% |
| Civilian labor force B23025 | 33,374 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 24.7 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 67.7% | 43.2% | 37.1% |
| Housing units B25001 | 26,230 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 66.5% | 54.6% | 55.9% |
| Renters B25003 | 33.5% | 45.4% | 44.1% |
| Median home value B25077 | $1,646,800 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,886 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 73.3% | 42.4% | 33.8% |
| Black B03002 | 0.4% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 16.4% | 34.6% | 40.2% |
| Asian B03002 | 4.2% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Encinitas, CA.
Comments